Picture loading failed.

Anti-CD3E therapeutic antibody (Pre-made Teplizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Teplizumab (also known as PRV-031; formerly also known as MGA031 and hOKT3γ1(Ala-Ala)) is a humanized anti-CD3 monoclonal antibody that is being evaluated for treatment and prevention of type 1 diabetes mellitus (T1DM) by the biopharmaceutical company Provention Bio. Teplizumab has also been evaluated for treatment of renal allograft rejection, for induction therapy in islet transplant recipients, and for psoriatic arthritis.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-562-1mg 1mg 3090
GMP-Bios-ab-562-10mg 10mg 21890
GMP-Bios-ab-562-100mg 100mg 148000
GMP-Bios-ab-562-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CD3E therapeutic antibody (Pre-made Teplizumab biosimilar,Whole mAb)
INN Name Teplizumab
TargetCD3E
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Preregistration
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2007
Year Recommended2008
CompaniesImmune Tolerance Network;MacroGenics;National Institute of Diabetes and Digestive and Kidney Diseases;National Institutes of Health (USA);Provention Bio;Tolerance Therapeutics
Conditions Approvedna
Conditions ActiveType 1 diabetes mellitus
Conditions DiscontinuedMultiple sclerosis;Psoriasis;Psoriatic arthritis
Development Techna